Add to ORKGAn implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM
The use of Instanyl ® in the treatment of breakthrough pain in cancer patients: a 3-month observatio...
Implant Relieves Chronic Pain, Delivers Drug Directly to Central Nervous System New Drug Combination...
Intrathecal drug delivery is an effective pain management option for patients with chronic and cance...
BACKGROUND: The randomized clinical trial of implantable drug delivery systems (IDDS) plus comprehen...
PURPOSE: Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory c...
Between 10% and 20% of cancer pain patients fail to obtain adequate pain relief despite comprehensiv...
Introduction: A substantial number of patients with cancer suffer considerable pain at some point du...
BackgroundCancer pain prevalence remains high with more than 60% of patients with advanced cancer ex...
Pain is prevalent in advanced malignancies; however, some patients cannot get adequate pain relief b...
Background/PurposeBetween 10% and 20% of cancer pain patients fail to obtain adequate pain relief de...
Topically applied pharmaceuticals in the form of patches that distribute medications for systemic ef...
Intrathecal drug delivery is an effective pain management option for patients with chronic and cance...
In the recent scenario of the world there are millions of the people are suffering from the various ...
Journal Article;Breakthrough cancer pain is defined as transient pain exacerbation in patients with ...
Cancer is the 2nd leading cause of death in the world and killed 8.8 million people in 2015 alone. [...
The use of Instanyl ® in the treatment of breakthrough pain in cancer patients: a 3-month observatio...
Implant Relieves Chronic Pain, Delivers Drug Directly to Central Nervous System New Drug Combination...
Intrathecal drug delivery is an effective pain management option for patients with chronic and cance...
BACKGROUND: The randomized clinical trial of implantable drug delivery systems (IDDS) plus comprehen...
PURPOSE: Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory c...
Between 10% and 20% of cancer pain patients fail to obtain adequate pain relief despite comprehensiv...
Introduction: A substantial number of patients with cancer suffer considerable pain at some point du...
BackgroundCancer pain prevalence remains high with more than 60% of patients with advanced cancer ex...
Pain is prevalent in advanced malignancies; however, some patients cannot get adequate pain relief b...
Background/PurposeBetween 10% and 20% of cancer pain patients fail to obtain adequate pain relief de...
Topically applied pharmaceuticals in the form of patches that distribute medications for systemic ef...
Intrathecal drug delivery is an effective pain management option for patients with chronic and cance...
In the recent scenario of the world there are millions of the people are suffering from the various ...
Journal Article;Breakthrough cancer pain is defined as transient pain exacerbation in patients with ...
Cancer is the 2nd leading cause of death in the world and killed 8.8 million people in 2015 alone. [...
The use of Instanyl ® in the treatment of breakthrough pain in cancer patients: a 3-month observatio...
Implant Relieves Chronic Pain, Delivers Drug Directly to Central Nervous System New Drug Combination...
Intrathecal drug delivery is an effective pain management option for patients with chronic and cance...